Delving into the Latest Updates on BI-905677 with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

BI 905677

Target

LRP5 x LRP6

Mechanism

LRP5 inhibitors(LDL receptor related protein 5 inhibitors), LRP6 inhibitors(LDL receptor related protein 6 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Boehringer Ingelheim GmbH

Active Organization-

Inactive Organization

Boehringer Ingelheim GmbH

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful. The purpose of this study is to find out the highest dose of BI 905677 the participants can tolerate. BI 905677 is a type of an antibody that is being developed to treat cancer.
One dose of BI 905677 is given to the participants every 2 or 3 weeks as infusion into a vein. In this study, BI 905677 is given to humans for the first time. The participants visit the study site at least once a week so that the doctors can check their general health. The participants are in the study for as long as they benefit from and can tolerate treatment.

Start Date08 Aug 2018

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with BI-905677

Login to view more data

100 Translational Medicine associated with BI-905677

Login to view more data

100 Patents (Medical) associated with BI-905677

Login to view more data

100 Deals associated with BI-905677

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	US	Boehringer Ingelheim GmbH	08 Aug 2018
Advanced Malignant Solid Neoplasm	Phase 1	JP	Boehringer Ingelheim GmbH	08 Aug 2018
Advanced Malignant Solid Neoplasm	Phase 1	NL	Boehringer Ingelheim GmbH	08 Aug 2018
Advanced Malignant Solid Neoplasm	Phase 1	ES	Boehringer Ingelheim GmbH	08 Aug 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03604445 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	37	BI 905677 (BI 905677 0.05 mg/kg)	ncuqfyfqwk(zgjysyagsl) = bycurjuwgg zuncwejldc (odhqmuitay, lmlwxohhfi - lesyxtocit) View more	-	04 Mar 2024
NCT03604445 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	37	BI 905677 (BI 905677 0.1 mg/kg)	ncuqfyfqwk(zgjysyagsl) = aqktgcvdem zuncwejldc (odhqmuitay, yumruozqev - uqfwfkyiew) View more	-	04 Mar 2024
NCT03604445 (AACR2022) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	37	BI 905677	xoncacdwik(gbyqvwwfpm) = cfoelbpkgs avjcolrpcm (vkjoknoomy ) View more	Positive	15 Jun 2022